We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.34%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$15.4M
(-4.2%)
Cap. Flow
+$604K
Cap. Flow
% of AUM
0.17%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
95
New
24
Increased
19
Reduced
22
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$12.6M |
| 2 |
Pfizer
PFE
|
+$11.1M |
| 3 |
HOLX
Hologic
HOLX
|
+$9M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.71M |
| 5 |
Lifestance Health
LFST
|
+$6.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$12.1M |
| 2 |
Cytokinetics
CYTK
|
+$11M |
| 3 |
Elevance Health
ELV
|
+$9.5M |
| 4 |
Sanofi
SNY
|
+$9.22M |
| 5 |
LHCG
LHC Group LLC
LHCG
|
+$8.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.71% |
| 2 | Energy | 0% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $17.9M | 5.14% |
300,000
+75,000
| +33% | +$4.43M |
|
2
Acadia Healthcare
ACHC
$2.83B
| $16.3M | 4.68% |
255,000
-5,000
| -2% | -$316K |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $14.1M | 4.06% |
319,000
+95,000
| +42% | +$4.36M |
|
|
4
CVS Health
CVS
$133B
| $12.7M | 3.66% |
+150,000
| New | +$12.6M |
|
|
5
Cytokinetics
CYTK
$10.5B
| $11.6M | 3.34% |
325,000
-375,000
| -54% | -$11M |
|
6
Globus Medical
GMED
$11B
| $11.5M | 3.3% |
150,000
+20,000
| +15% | +$1.61M |
|
|
7
Pfizer
PFE
$143B
| $10.8M | 3.09% |
+250,000
| New | +$11.1M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $10.1M | 2.9% |
98,000
-2,000
| -2% | -$186K |
|
9
Medtronic
MDT
$110B
| $10M | 2.88% |
80,000
| – | – |
|
10
Envista
NVST
$4.51B
| $9.62M | 2.76% |
230,000
+50,000
| +28% | +$2.11M |
|
|
11
Elevance Health
ELV
$82.2B
| $9.32M | 2.68% |
25,000
-25,000
| -50% | -$9.5M |
|
|
HOLX
12
DELISTED
Hologic
HOLX
| $8.86M | 2.55% |
+120,000
| New | +$9M |
|
13
Zimmer Biomet
ZBH
$18.4B
| $8.78M | 2.52% |
61,800
+25,750
| +71% | +$3.79M |
|
14
Revvity
RVTY
$12.4B
| $8.66M | 2.49% |
50,000
+10,000
| +25% | +$1.76M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.79M | 1.95% |
+40,000
| New | +$6.23M |
|
16
Intellia Therapeutics
NTLA
$1.54B
| $6.71M | 1.93% |
50,000
+20,000
| +67% | +$3.03M |
|
|
HZNP
17
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.57M | 1.89% |
+60,000
| New | +$6.23M |
|
|
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
| $6.26M | 1.8% |
190,000
+155,000
| +443% | +$8.71M |
|
19
Centene
CNC
$31.6B
| $6.23M | 1.79% |
+100,000
| New | +$6.68M |
|
20
Regeneron Pharmaceuticals
REGN
$77.8B
| $6.05M | 1.74% |
10,000
-8,500
| -46% | -$5.28M |
|
21
Zentalis Pharmaceuticals
ZNTL
$343M
| $6M | 1.72% |
90,000
-35,000
| -28% | -$2.02M |
|
22
Fate Therapeutics
FATE
$284M
| $5.63M | 1.62% |
95,000
+15,000
| +19% | +$1.18M |
|
23
DexCom
DXCM
$32.9B
| $5.47M | 1.57% |
+40,000
| New | +$5.04M |
|
|
CCXI
24
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.13M | 1.47% |
300,000
+125,000
| +71% | +$1.95M |
|
|
25
Lifestance Health
LFST
$3.93B
| $5.08M | 1.46% |
+350,000
| New | +$6.74M |
|
Similar funds
CL
ACM
NSCM
ACG
NSUP
TP
ACP
TA
Integral Health Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Integral Health Asset Management held 95 positions worth $348M, down 4.2% from $363M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management's Q3 2021 filing shows 24 new, 19 increased, 22 reduced and 25 closed positions. Its largest new stake was CVS Health: 150,000 shares worth $12.7M. The largest sale was Biogen, an estimated $12.1M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Energy and Industrials.
- Integral Health Asset Management's largest Q3 2021 buy was CVS Health: 150,000 shares worth $12.7M.
- Integral Health Asset Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $8.71M increase.
- Integral Health Asset Management's biggest Q3 2021 reduction was Cytokinetics, cutting an estimated $11M.
- Integral Health Asset Management fully exited Biogen in Q3 2021, selling an estimated $12.1M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $348M portfolio in Q3 2021.
- Integral Health Asset Management opened 24 new positions and closed 25 in Q3 2021.
- Integral Health Asset Management's portfolio value fell 4.2% quarter-over-quarter to $348M.
Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.